98135-75-2

Basic information

• Product Name: Cyclobutanol, 1-ethynyl-
• CAS NO: 98135-75-2
• Molecular Formula: C6H8O
• Molecular Weight: 96.1289
• Mol File: 98135-75-2.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: Cyclobutanol, 1-ethynyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclobutanol, 1-ethynyl-(98135-75-2)
• EPA Substance Registry System: Cyclobutanol, 1-ethynyl-(98135-75-2)

Safety Data

• Hazardous Substances Data: 98135-75-2(Hazardous Substances Data)

Upstream product

• 1191-95-3 cyclobutanone 
• 74-86-2 acetylene 
• 65032-27-1 ethynylmagnesium chloride 
• 4301-14-8 acetylenemagnesium bromide 

Relevant articles and documents

A Highly Efficient Dimeric Manganese-Catalyzed Selective Hydroarylation of Internal Alkynes

We have developed a general and site-predictable manganese-catalyzed hydroarylation of internal alkynes in the presence of water, under an air atmosphere without the involvement of ligand. The unique catalytic feature of this reaction is highlighted by comparison with other widely used transition metal catalysts including palladium, rhodium, nickel, or copper. The simple operation, high efficiency and excellent functional group compatibility make this protocol practical for more than 90 structurally diverse internal alkynes, overcoming the influence of both electronic and steric effect of alkynes. Its exclusive regio- and chemoselectivity originates from the unique reactivity of the manganese-based catalyst towards an inherent double controlled strategy of sterically hindered propargyl alcohols without the installing of external directing groups. Its synthetic robustness and practicality have been illustrated by the concise synthesis of bervastatin, a hypolipidemic drug, and late-stage modification of complex alkynes with precise regioselectivity.

SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINECOMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF

Disclosed are HPK-1 inhibitors having a structure represented by Formula (X), pharmaceutical compositions comprising the HPK-1 inhibitors, methods of using the HPK-1 inhibitors, such as treating cancers, methods of preparing the HPK-1 inhibitors, and the synthetic intermediates.